Detailed explanation of the efficacy and role of Vancevir/Valganciclovir Hydrochloride Tablets

Valganciclovir is an antiviral drug used to treat cytomegalovirus (CMV) infection. As the L-valyl ester of ganciclovir, it is actually a prodrug of ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. Thereafter, it (an analog of guanosine) is integrated into the DNA and therefore cannot be read correctly by DNA polymerase, which leads to the termination of viral DNA elongation.

Valganciclovir is a prodrug of ganciclovir and exists as a mixture of two diastereoisomers. Following administration, these diastereomers are rapidly converted to ganciclovir by hepatic and intestinal esterases. In cells infected with cytomegalovirus (CMV), ganciclovir is initially phosphorylated by viral protein kinases to the monophosphate form and then further phosphorylated by cellular kinases to produce the triphosphate form. This triphosphate form is metabolized slowly within cells. Phosphorylation is dependent on viral kinases and occurs preferentially in virus-infected cells.

The viral inhibitory activity of ganciclovir is due to the inhibitory effect of ganciclovir triphosphate on viralDNA synthesis. Ganciclovir triphosphate is incorporated into the DNA strand, replacing many of the adenosine bases. This leads to a block in DNA synthesis, as phosphodiester bridges can take longer to establish, destabilizing the chain. Ganciclovir inhibits viral DNA polymerase more efficiently than cellular polymerase, and chain elongation resumes when ganciclovir is removed.

Valganciclovir Hydrochloride Tablets are an oral administration form that can be rapidly absorbed in the body and has high bioavailability. This makes it easier for patients to take medication and improves the effectiveness of treatment. Valganciclovir hydrochloride tablets have been widely used clinically and have been proven to be relatively safe and tolerable.